Use of ultrarapid acting insulin
Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
1. A method of treating hyperglycemia in a patient with diabetes, comprising
administering to said patient in need thereof and having a hemoglobin A1C level ≥6.0% a combination of an ultrarapid acting insulin and a long acting insulin analog,
wherein the ultrarapid insulin comprises a dose comprising one or more cartridges of up to 32 units of said ultrarapid insulin formulation administered at mealtime by oral inhalation, and a first dose of the long-acting insulin analog is administered within 6 hours of waking, and optionally, administering a second dose of the long acting insulin at 8 to 14 hours after said first dose of the long-acting insulin, wherein said method further comprises determining the ultrarapid insulin dose for a carbohydrate meal content and administering a predetermined dosage of the ultrarapid acting insulin formulation at mealtime for each daily meal.
2. The method of claim 1 , wherein the long acting insulin analog is administered within 3 hours of waking in the morning.
3. The method of claim 1 , wherein the long acting insulin analog is insulin detemir or insulin glargine.
4. The method of claim 1 , wherein the long acting insulin is insulin glargine.
5. The method of claim 1 , wherein the ultrarapid acting insulin comprises a dry powder formulation comprising recombinant human insulin and a 3,6-di(fumaryl-4-aminobutyl)-2,5-diketopiperazine.
6. The method of claim 1 , wherein the ultrarapid acting insulin comprises crystalline microparticles of the recombinant insulin and the a 3,6-di(fumaryl-4-aminobutyl)-2,5-diketopiperazine.
7. The method of claim 1 , wherein the ultrarapid acting insulin is administered using a dry powder inhaler.
8. The method of claim 1 , wherein the hyperglycemia is resultant of diabetes type 2.
9. The method of claim 1 , wherein said carbohydrate meal content is ≥25%, to ≤200% of a usual meal content as used in determination of the predetermined dose.
10. The method of claim 1 , wherein the ultrarapid acting insulin formulation is insulin-FDKP.
11. A method of treating hyperglycemia in a patient in need thereof with a combination of an inhalable ultrarapid acting insulin and an exogenous basal insulin comprising administering the inhalable ultrarapid insulin with a meal, and continuously infusing a short acting insulin with an insulin pump throughout the day.
12. The method of claim 11 , wherein the short-acting insulin is a recombinant human insulin or a rapid acting insulin analog.